CRNX Crinetics Corp: Price-to-Projected Revenue Ratio

Crinetics Pharmaceuticals - graphic logo of issuer CRNX

The delivery of Crinetics Pharmaceuticals (CRNX) drugs requires strict temperature control via expensive courier services. The company's future P/S on the GURU.Markets analytical chart captures the dynamics of market value relative to revenue forecasts, where 213.40 is recorded as the baseline value. The development of oral endocrinology treatments is replacing injections, while external manufacturing risks are mitigated through laboratory diversification and rigorous quality control.

Crinetics - CRNX Market Cap to Expected Sales Ratio (period 07/04/2022 - 09/12/2026)

Summary analytical data breakdowns for Crinetics Pharmaceuticals (CRNX)

- market price and analyst price targets:
Price Chart crinetics.com|CRNX - Average Forecast Price
- company stock capitalization data:
Market Value Crinetics Pharmaceuticals|CRNX - Total Company Value
- book value of equity indicators:
Book Value per Share Crinetics|CRNX - Book Valuation of Business|Market Value to Book Value Ratio crinetics.com|CRNX - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Crinetics Pharmaceuticals|CRNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Crinetics Pharmaceuticals, Inc.|CRNX - Company Total Debt|Debt to Book Capitalization Ratio Crinetics Pharmaceuticals, Inc.|CRNX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Crinetics|Quick Liquidity crinetics.com
- financial results and valuation multiples details:
CRNX - Company Profit|Projected Future Earnings Crinetics Pharmaceuticals|CRNX - Market Cap to Earnings|Projected Price to Earnings Crinetics Pharma|CRNX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Crinetics Pharma|CRNX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Crinetics|CRNX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months crinetics.com|CRNX - Expected net earnings per share growth this year|Expected earnings per share growth for next year Crinetics Pharmaceuticals
- sales volume and revenue indicators:
CRNX - Company Sales Revenue|Company Projected Revenue Crinetics|CRNX - Price-to-Sales Ratio|Forward P/S Multiple Crinetics Pharmaceuticals, Inc.|CRNX - Revenue Dynamics YoY (Last Twelve Months)
Analysis of all company metrics:CRNX (Crinetics Pharma)
Original product of Crinetics Corp

To objectively value an issuer, it is essential for a portfolio manager to understand the ratio of current market capitalization to projected revenue, adjusted for the cost of capital. By analyzing the expected P/S ratio, an investor identifies the risk of stock overvaluation amid rising interest rates, which is critical for Crinetics Pharmaceuticals (CRNX), as its market value is based on the potential of high-margin drugs for treating rare endocrine pathologies.

Key competitors

Price-to-Projected Revenue Ratio ascendispharma.com ASND|Madrigal Corp (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake Corp|NewAmsterdam Pharma Corp (NAMS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio soleno.life (SLNO)|Forward Price-to-Revenue Multiple Amicus Therapeutics FOLD|Forward Price to Sales 89bio Inc|Forward P/S Multiple Agios Pharmaceuticals, Inc. AGIO|GPCR: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio MiMedx Corp MDXG|RZLT (Rezolute Corp) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue LXRX|MBX (MBX Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Altimmune Inc (ALT)|Forward Price-to-Revenue Multiple AARD (Aardvark Therapeutics Corp)|Forward Price-to-Revenue Multiple Sagimet SGMT|Forward P/S Multiple BIOA (BioAge Labs)|Forward P/S Multiple Biomea Fusion BMEA|QNCX: Forward Price-to-Revenue Multiple|GUTS: Price-to-Projected Revenue Ratio|vTv Therapeutics Inc (VTVT) - Price-to-Projected Revenue Ratio|ATPC: Price to Expected Revenue Ratio|PLUR (pluri-biotech.com) - Forward P/S Multiple|SYBX: Forward Price to Sales|Forward P/S Multiple LPCN|Market Cap to Expected Sales Ratio Matinas BioPharma Holdings, Inc.|Price-to-Projected Revenue Ratio Spruce Biosciences Inc. SPRB|GLTO - Forward Price-to-Revenue Multiple|CTCX - Price-to-Projected Revenue Ratio|LUMO - Forward P/S Multiple|ONVO: Forward P/S Multiple|RDUS (Radius Recycling) - Price-to-Projected Revenue Ratio